Subscribe To
TVTX / Travere: Turbulent Journey With FILSPARI, Downgrading To Sell
TVTX News
By GlobeNewsWire
October 24, 2023
Travere Therapeutics to Report Third Quarter 2023 Financial Results
SAN DIEGO, Oct. 24, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report third quarter 2023 financial res more_horizontal
By GlobeNewsWire
October 13, 2023
Travere Therapeutics to Present Abstracts at the American Society of Nephrology (ASN) Kidney Week 2023
Two late-breaking high-impact oral presentations of the Phase 3 PROTECT Study of FILSPARI ® (sparsentan) in IgAN and Phase 3 DUPLEX Study of sparsent more_horizontal
By GlobeNewsWire
September 26, 2023
Travere Therapeutics to Present Abstracts at the 17th International Symposium on IgA Nephropathy (IIGANN 2023)
SAN DIEGO, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that the Company and its collaborators will pr more_horizontal
By Zacks Investment Research
September 22, 2023
Travere (TVTX) Slumps 41% on Mixed Results From IgAN Drug Study
Data from a confirmatory study shows that Travere's (TVTX) IgAN therapy did not achieve one of its confirmatory secondary endpoints. This will likely more_horizontal
By The Motley Fool
September 21, 2023
Why Shares of Travere Therapeutics Are Slumping Thursday
Travere said that Filspari was promising in preserving kidney function. The therapy did not meet all of its endpoints in a phase 3 trial. more_horizontal
By GlobeNewsWire
August 24, 2023
Travere Therapeutics to Present Abstracts at the Society for the Study of Inborn Errors of Metabolism Annual Symposium 2023
SAN DIEGO, Aug. 24, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that the Company will present clinical data fro more_horizontal
By Zacks Investment Research
August 3, 2023
Travere (TVTX) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
Although the revenue and EPS for Travere (TVTX) give a sense of how its business performed in the quarter ended June 2023, it might be worth consideri more_horizontal
By Zacks Investment Research
August 3, 2023
Travere Therapeutics (TVTX) Reports Q2 Loss, Tops Revenue Estimates
Travere Therapeutics (TVTX) came out with a quarterly loss of $1.13 per share versus the Zacks Consensus Estimate of a loss of $1.16. This compares to more_horizontal